Indian Health Service
National Pharmacy and Therapeutics Committee
NPTC Fall Meeting Update
-November 2016-

The Indian Health Service (IHS) National Pharmacy and Therapeutics Committee (NPTC) held its fall meeting on November 3rd, 2016 via teleconference. All 12 IHS Areas were represented. Dr. Caroline Badeer, MD, and Christopher Pack, PharmD, both served as subject matter experts and delivered presentations to the NPTC. Affiliates from the Department of Veterans Affairs, Department of Defense, Federal Bureau of Prisons and Centers for Disease Control and Prevention provided input and updates on clinical experiences and future meeting topics. The NPTC continues to value the relationships with experts from the field and with the federal partners. Additionally, the NPTC appreciated the opportunity to host the teleconference from the Oklahoma City Area Office.

The NPTC received a drug class review of the serotonin 5-HT $_{1b/1d}$ receptor agonists (aka "triptans"), a clinical presentation on biosimilar medications and a brief clinical update from the IHS National Pharmacy Council's Antibiotic Stewardship Program.

The resulting action(s) from the meeting were as follows:

1. A class review of the serotonin 5-HT $_{1b/1d}$ receptor agonists (aka "triptans") was delivered, which included all routes of administration for almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, sumatriptan/naproxen and zolmitriptan. Agency-specific utilization and procurement data were also presented. Currently, the IHS National Core Formulary (NCF) maintains that any triptan agent is acceptable so long as one agent is represented on federal facilities' drug formulary. Numerous systematic reviews, meta-analyses and clinical practice guidelines were provided for this review, along with analyses from partnering federal agencies on comparative class reviews. As a result of this evaluation, **the NPTC ADDED any two serotonin 5-HT $_{1b/1d}$ receptor agonists, one of which must be sumatriptan to the NCF.** Key decisional points leading to this NCF addition will be detailed in the upcoming NPTC Formulary Brief.

2. A clinical presentation on biosimilar medications was also provided to the Committee. Currently, there are 4 FDA-approved agents with this designation including filgrastim-sndz (Zarxio®), infliximab-dyyb (Inflectra®), etanercept-szzs (Erelzi®) and adalimumab-atto (Amjevita®). Presently, only filgrastim-sndz is currently marketed in the U.S. and available for purchase. The remaining approved biosimilar products are awaiting a legally mandated 180-day window (from FDA approval date) to begin product sales. **No changes were made to the IHS NCF.**

**The next NPTC meeting will be February 7-8th, 2017 in Phoenix, AZ. The agenda will include an overview of metabolic syndrome along with presentations on the treatment of insulin resistance and prediabetes, hyperlipidemia (associated with metabolic syndrome), nonalcoholic fatty liver disease and polycystic ovarian syndrome. A medication class review of the SGLT-2 Inhibitors will also be provided.

If you would like to recommend a topic for future NPTC discussion, please complete the quick-and-easy NPTC Formulary Request Form or simply send an email to IHSNPTC1@ihs.gov.

For more information about the NPTC including past or present Formulary Briefs or the National Core Formulary, please visit the NPTC website. ***Check out the new webpage design and functionality!!***